Cellarity to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Section HeadingSection Content

Somerville, Mass., January 3, 2024 – Cellarity Inc., a life sciences company founded by Flagship Pioneering to fundamentally transform the way drugs are created and design medicines currently out of reach, announced today that Fabrice Chouraqui, CEO of Cellarity, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis on Thursday, January 11, 2024, at 7:30 a.m. PT.

A copy of the company’s presentation will be made available on the company’s website following the event.

About Cellarity

Cellarity is fundamentally redesigning the way drugs are created. By shifting our scientific focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with a target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including metabolic disease, hematology, and immunology. For more information, visit www.cellarity.com.

Up Next

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases